In order to evaluate the relationship of sleep disturbance to the antidepressant effects of esketamine, 2 double-blind, 4-week studies randomized adults with treatment-resistant depression (TRD) to placebo or esketamine nasal spray.
In an interview, sleep medicine experts Milena K Pavlova, MD, and Rachel Ziegler, MD, discuss the latest developments in sleep disorder therapies and the existing gaps in sleep medicine.
Researchers assessed whether zolpidem (priming) is required for partial reinforcement or whether intermittent dosing with placebos can be effective for acute and extended treatment for patients with chronic insomnia.
Melatonin and other melatonin receptor agonists have demonstrated efficacy in the treatment of circadian rhythm disorders in both pediatric and adult populations.
In patients with episodic migraines, the occurrence of a migraine headache does not consistently impact nighttime sleep.
A substantial percentage of Medicare beneficiaries with sleep disorders (most commonly insomnia and obstructive sleep apnea) undergo evaluations by sleep specialists.
Conducting only a single night of portable monitoring can misclassify disease severity in patients with mild to moderate sleep apnea.
Solriamfetol offers short-term improvements in functional status, health-related quality of life, and work productivity in people with narcolepsy.
Researchers report the need for more child neurology trainees to enter a sleep medicine fellowship in an effort to improve the outcomes of children with neurologic disorders that may be linked to sleep disruption.
Postmenopausal women more often have sleep-onset insomnia disorder and are more likely to screen positive for obstructive sleep apnea.
